<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04153760</url>
  </required_header>
  <id_info>
    <org_study_id>REB19-1237</org_study_id>
    <nct_id>NCT04153760</nct_id>
  </id_info>
  <brief_title>Pilot PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity</brief_title>
  <acronym>PARTUM</acronym>
  <official_title>A Pilot Study Assessing the Feasibility of a Randomized Controlled Trial Evaluating Aspirin in Postpartum Women at Risk of Developing Venous Thromboembolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The pilot PARTUM trial is a randomized, multicenter, placebo-controlled trial. Women who are&#xD;
      at modest risk of VTE (as defined by the inclusion criteria) will be identified during&#xD;
      pregnancy, labor and delivery and up to 48 hours postpartum. Eligible and consenting&#xD;
      participants will be randomly assigned to one of two study arms: aspirin 81 mg daily or&#xD;
      placebo daily for 6 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the pilot PARTUM trial is to determine whether it is feasible to conduct a&#xD;
      larger randomized controlled trial to determine whether low-dose aspirin is efficacious and&#xD;
      safe at preventing postpartum venous thromboembolism (VTE) in women at increased risk of VTE,&#xD;
      compared to placebo.&#xD;
&#xD;
      Given the large sample size needed to adequately power a large multicenter trial that&#xD;
      assesses the efficacy of aspirin 81 mg versus placebo, the investigators first need to&#xD;
      determine if it is possible to recruit enough women. If the pilot trial is successful and&#xD;
      there are no major changes to the study design, then the secondary clinical outcomes&#xD;
      collected in the pilot trial will be used in the analysis of the full multicenter trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 7, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recruitment Rate</measure>
    <time_frame>6 months</time_frame>
    <description>Mean recruitment rate per center per month</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Consent Rate</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of eligible subjects who provide consent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Withdrawals/Loss to Follow-up</measure>
    <time_frame>9 months</time_frame>
    <description>Proportion of withdrawals/loss to follow-up among participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study Drug Compliance</measure>
    <time_frame>6 months</time_frame>
    <description>Level of compliance with study drug through participant recall and medication diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Required to Obtain Site Institutional Approvals</measure>
    <time_frame>24 months</time_frame>
    <description>Proportion of sites requiring &gt;18 months to obtain all required approvals/contracts from time of delivery of all study documents.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VTE Event Rate</measure>
    <time_frame>6 months</time_frame>
    <description>A more precise estimate of the VTE event rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Event Rate</measure>
    <time_frame>6 months</time_frame>
    <description>A more precise estimate of the major and clinically relevant non-major bleeding event rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">336</enrollment>
  <condition>Venous Thromboembolism</condition>
  <condition>Postpartum Period</condition>
  <condition>Aspirin</condition>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin 81 mg daily for six weeks post-randomization (postpartum)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo daily for six weeks post-randomization (postpartum)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 81 mg</intervention_name>
    <description>Aspirin 81 mg p.o. daily</description>
    <arm_group_label>Aspirin</arm_group_label>
    <other_name>acetylsalicylic acid</other_name>
    <other_name>ASA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo p.o. daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Study inclusion criteria includes one (or more) first order criterion&#xD;
        or two (or more) second order criteria. A patient is still eligible if they have multiple&#xD;
        criteria met, at the discretion of the local investigator.&#xD;
&#xD;
        ONE (or more) First Order Criteria:&#xD;
&#xD;
          1. Known inherited thrombophilia diagnosed prior to enrolment:&#xD;
&#xD;
             i) Heterozygous factor V Leiden, OR ii) Heterozygous prothrombin gene variant, OR iii)&#xD;
             Protein C deficiency, OR iv) Protein S deficiency&#xD;
&#xD;
          2. Immobilization (90% of waking hours spent in bed) for ≥7 days anytime during the&#xD;
             antepartum period&#xD;
&#xD;
        TWO (or more) Second Order Criteria:&#xD;
&#xD;
          1. Postpartum infection&#xD;
&#xD;
          2. Postpartum hemorrhage (&gt;1000 mL of blood loss, regardless of delivery mode)&#xD;
&#xD;
          3. Pre-pregnancy BMI ≥30 kg/m2&#xD;
&#xD;
          4. Emergency or unplanned cesarean delivery&#xD;
&#xD;
          5. Smoking ≥5 cigarettes/day before pregnancy&#xD;
&#xD;
          6. Pre-eclampsia&#xD;
&#xD;
          7. Current pregnancy ending in stillbirth (pregnancy loss &gt;20 weeks gestation)&#xD;
&#xD;
          8. Small-for-gestational-age infant (&lt;3rd percentile adjusted for gestational age and&#xD;
             sex).&#xD;
&#xD;
          9. Previous history of superficial vein thrombosis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. More than 48 hours since delivery&#xD;
&#xD;
          2. Received more than 2 doses of low-molecular-weight heparin (LMWH) since delivery&#xD;
&#xD;
          3. Need for postpartum LMWH prophylaxis or systemic anticoagulation as judged by the&#xD;
             local investigator. May include but is not limited to:&#xD;
&#xD;
               1. Documented history of provoked or unprovoked VTE&#xD;
&#xD;
               2. Mechanical heart valve(s)&#xD;
&#xD;
               3. Known antiphospholipid syndrome&#xD;
&#xD;
               4. Known high-risk inherited thrombophilia i) Antithrombin deficiency; ii)&#xD;
                  Homozygous factor V Leiden; iii) Homozygous prothrombin gene mutation; iv)&#xD;
                  Compound heterozygosity factor V Leiden and prothrombin gene mutation; v) More&#xD;
                  than one inherited thrombophilia&#xD;
&#xD;
          4. Need for postpartum aspirin as judged by the local investigator. May include but is&#xD;
             not limited to:&#xD;
&#xD;
               1. Documented history of myocardial infarction&#xD;
&#xD;
               2. Documented history of ischemic stroke or transient ischemic attack (TIA)&#xD;
&#xD;
          5. Contraindication to aspirin including:&#xD;
&#xD;
               1. History of known aspirin allergy&#xD;
&#xD;
               2. Documented history of a gastrointestinal ulcer&#xD;
&#xD;
               3. Known platelet count &lt;50 x 109/L at any time during the current pregnancy or&#xD;
                  postpartum&#xD;
&#xD;
               4. Active bleeding at any site, excluding normal vaginal bleeding, at the time of&#xD;
                  randomization&#xD;
&#xD;
               5. Most recent known hemoglobin ≤70 g/L documented during the current pregnancy or&#xD;
                  postpartum&#xD;
&#xD;
               6. Known severe hypertension (SBP &gt;200mm/hg and/or DBP &gt;120mm/hg) during the current&#xD;
                  pregnancy or postpartum&#xD;
&#xD;
          6. &lt;18 years of age&#xD;
&#xD;
          7. Unable or refused consent&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leslie Skeith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc Rodger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Hospital Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leslie Skeith, MD</last_name>
    <phone>403-944-5246</phone>
    <email>laskeith@ucalgary.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandra Garven, BSc</last_name>
    <phone>403-220-7631</phone>
    <email>alexandra.garven@ucalgary.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Skeith, MD</last_name>
      <phone>403-944-5246</phone>
      <email>laskeith@ucalgary.ca</email>
    </contact>
    <contact_backup>
      <last_name>Alexandra Garven, BSc</last_name>
      <phone>403-944-5246</phone>
      <email>alexandra.garven@ucalgary.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 4, 2019</study_first_submitted>
  <study_first_submitted_qc>November 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2019</study_first_posted>
  <last_update_submitted>October 16, 2020</last_update_submitted>
  <last_update_submitted_qc>October 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>deep vein thrombosis</keyword>
  <keyword>pulmonary embolism</keyword>
  <keyword>postpartum</keyword>
  <keyword>pregnancy</keyword>
  <keyword>thrombophilia</keyword>
  <keyword>cesarean delivery</keyword>
  <keyword>pre-eclampsia</keyword>
  <keyword>postpartum hemorrhage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

